SCYNEXIS/SCYX

$1.62

0%
-
1D1W1MYTD1YMAX

About SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.

Ticker

SCYX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Angulo

Employees

36

Headquarters

Jersey city, United States

SCYNEXIS Metrics

BasicAdvanced
$60.28M
Market cap
1.16
P/E ratio
$1.40
EPS
1.59
Beta
-
Dividend rate

What the Analysts think about SCYNEXIS

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
401.85% upside
High $10.00
Low $7.00
$1.62
Current price
$8.13
Average price target

SCYNEXIS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-100% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$1.7M
-98.71%
Net income
$-1.7M
-101.39%
Profit margin
-100%
-207.54%

SCYNEXIS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 72.6%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.37
-$0.71
$2.46
-$0.04
-
Expected
-$0.44
-$0.28
$1.55
-$0.15
-$0.20
Surprise
-15.91%
155.4%
58.91%
-72.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell SCYNEXIS stock

Buy or sell SCYNEXIS stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing